Barclays PLC increased its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 444.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 704,371 shares of the company's stock after purchasing an additional 575,069 shares during the quarter. Barclays PLC owned approximately 0.83% of Terns Pharmaceuticals worth $3,903,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of the company. Landscape Capital Management L.L.C. bought a new stake in shares of Terns Pharmaceuticals during the fourth quarter valued at approximately $73,000. Townsquare Capital LLC acquired a new position in Terns Pharmaceuticals during the fourth quarter valued at approximately $76,000. Savant Capital LLC bought a new stake in Terns Pharmaceuticals in the fourth quarter valued at approximately $89,000. China Universal Asset Management Co. Ltd. raised its holdings in Terns Pharmaceuticals by 33.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,010 shares of the company's stock worth $100,000 after purchasing an additional 4,475 shares during the period. Finally, Stoneridge Investment Partners LLC bought a new position in Terns Pharmaceuticals during the fourth quarter worth about $114,000. Institutional investors own 98.26% of the company's stock.
Terns Pharmaceuticals Stock Down 2.9 %
Shares of TERN traded down $0.11 during midday trading on Friday, reaching $3.46. 509,447 shares of the stock were exchanged, compared to its average volume of 1,525,514. Terns Pharmaceuticals, Inc. has a twelve month low of $1.87 and a twelve month high of $11.40. The stock's 50 day simple moving average is $2.96 and its 200 day simple moving average is $4.79. The company has a market cap of $301.61 million, a P/E ratio of -2.93 and a beta of -0.13.
Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.06. As a group, analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.
Wall Street Analysts Forecast Growth
TERN has been the topic of several recent analyst reports. William Blair reiterated a "market perform" rating on shares of Terns Pharmaceuticals in a report on Friday, March 21st. JMP Securities reaffirmed a "market outperform" rating and issued a $20.00 price target on shares of Terns Pharmaceuticals in a research note on Monday, April 21st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, Terns Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.38.
View Our Latest Research Report on TERN
Terns Pharmaceuticals Profile
(
Free Report)
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Featured Articles

Before you consider Terns Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.
While Terns Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.